Engine Biosciences, a Singaporean company leveraging machine learning and high-throughput biology to discover and develop precision oncology medicines, has secured US$27 million in a Series A extension funding round led by Polaris Partners.
Existing backers ClavystBio, Invus, and EDBI, along with new investors Coronet Ventures and SEEDS Capital, also co-invested.
This round brings its total funds raised since its inception to US$86 million.
The biotech firm will use the funds to support the translation of R&D programmes derived from its proprietary NetMAPPR machine learning network biology platform and CombiGEM combinatorial genetics system into clinical settings.
Also Read: Singaporean biotech startup Automera secures US$16M Series A financing
Established in 2014, Engine Biosciences discovers and develops impactful precision medicines by deciphering complex biology with integrated computation and experimentation, with particular depth in oncology. The firm is advancing its pipeline of oncology therapeutics towards the clinic internally and with collaborators, and in other disease areas through partnerships.
Engine Biosciences has identified over 30 new precision medicine opportunities with validation data.
It has also reported the identification of new patient selection biomarkers for different targeted therapies, which have been validated to enhance tumour sensitivity to specific investigational drugs by 100 times. These biomarkers offer the potential for near-term improvements in clinical outcomes, commercial viability, and drug development economics.
“We have witnessed first-hand Engine Biosciences’s considerable progress since our initial investment, advancing its technologies towards compelling precision medicines positioned for translation,” said Amy Schulman, Managing Partner of Polaris Partners.
—
Fundraising or preparing your startup for fundraising? Build your investor network, search from 400+ SEA investors on e27, and get connected or get insights regarding fundraising. Try e27 Pro for free today.
The post Engine Biosciences lands US$27M to develop precision oncology drugs appeared first on e27.